» Articles » PMID: 21769105

Advances in Human Antiglomerular Basement Membrane Disease

Overview
Journal Nat Rev Nephrol
Specialty Nephrology
Date 2011 Jul 20
PMID 21769105
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Antiglomerular basement membrane (anti-GBM) disease is an autoimmune disorder that mostly presents as raised titers of antibodies against the GBM, rapidly progressive glomerulonephritis and pulmonary hemorrhage. The disease is caused by antibodies against noncollagenous domain of α3 chain of type IV collagen, which contains the epitopes E(A) and E(B). The humoral and cellular immunity contributing to the initiation of anti-GBM disease has been extensively studied as a model for autoimmune diseases, although most of the data come from animal studies. The disease is rare, but diagnoses have been made in hundreds of patients. Substantial advances have been made in the understanding of human anti-GBM disease, and it can be treated successfully. In this Review we summarize the current knowledge on the prevalence, clinical manifestations, treatment and outcomes of human anti-GBM disease. We discuss findings on pathogenesis from human studies, with close attention to disease initiation and the immunological features of progression from quiescent autoimmune homeostasis in healthy individuals to fulminant anti-GBM disease. Further studies on autoreactive T cells are expected to clarify specific features of human anti-GBM disease and could lead to the development of new therapies.

Citing Articles

Evaluation of the Risk Prediction Models in Predicting Kidney Outcomes in Antiglomerular Basement Membrane Disease.

Kuang H, Zhao Y, Wang J, Cui Z, Zhao M, Jia X Kidney Int Rep. 2024; 9(3):624-634.

PMID: 38481502 PMC: 10927471. DOI: 10.1016/j.ekir.2023.12.011.


Case report: renal recovery in Goodpasture's syndrome treated with rituximab.

Arnaert S, Schepens N, Deleu L, Malfait T J Nephrol. 2024; 37(5):1367-1370.

PMID: 38427310 DOI: 10.1007/s40620-024-01892-0.


Clinical and immunological characteristics of patients with combined anti-glomerular basement membrane disease and IgA nephropathy.

Shen C, Jia X, Cui Z, Yu X, Zhao M Clin Kidney J. 2023; 16(9):1480-1488.

PMID: 37664576 PMC: 10469093. DOI: 10.1093/ckj/sfad068.


Autoantibodies against laminin-521 are pathogenic in anti-glomerular basement membrane disease.

Kuang H, Shen C, Jia X, Tan M, Yang X, Cui Z Kidney Int. 2023; 104(6):1124-1134.

PMID: 37598856 PMC: 10840746. DOI: 10.1016/j.kint.2023.07.023.


Acute Ocular Complications after Recently Diagnosed Goodpasture's Syndrome - An Unusual Case of Hypertensive Retinopathy.

Eppenberger L, Schmid M, Clerici M Klin Monbl Augenheilkd. 2023; 240(4):505-508.

PMID: 37164428 PMC: 10129409. DOI: 10.1055/a-2034-6314.


References
1.
Hirayama K, Yamagata K, Kobayashi M, Koyama A . Anti-glomerular basement membrane antibody disease in Japan: part of the nationwide rapidly progressive glomerulonephritis survey in Japan. Clin Exp Nephrol. 2008; 12(5):339-347. DOI: 10.1007/s10157-008-0051-8. View

2.
Coutinho A, Kazatchkine M, Avrameas S . Natural autoantibodies. Curr Opin Immunol. 1995; 7(6):812-8. DOI: 10.1016/0952-7915(95)80053-0. View

3.
Zhao J, Cui Z, Yang R, Jia X, Zhang Y, Zhao M . Anti-glomerular basement membrane autoantibodies against different target antigens are associated with disease severity. Kidney Int. 2009; 76(10):1108-15. DOI: 10.1038/ki.2009.348. View

4.
Vanacore R, Ham A, Voehler M, Sanders C, Conrads T, Veenstra T . A sulfilimine bond identified in collagen IV. Science. 2009; 325(5945):1230-4. PMC: 2876822. DOI: 10.1126/science.1176811. View

5.
Yang R, Cui Z, Hellmark T, Segelmark M, Zhao M, Wang H . Natural anti-GBM antibodies from normal human sera recognize alpha3(IV)NC1 restrictively and recognize the same epitopes as anti-GBM antibodies from patients with anti-GBM disease. Clin Immunol. 2007; 124(2):207-12. DOI: 10.1016/j.clim.2007.05.001. View